27 October 2015 - ASCO today submitted comments to the Food and Drug Administration’s (FDA) on its proposed rule for the nonproprietary naming of biologic products, specifically biosimilars.

For more details, go to: http://www.asco.org/advocacy/asco-urges-fda-provide-clear-distinctions-between-biosimilars-and-approved-biological?et_cid=36899605&et_rid=977599084&linkid=ASCO+Urges+FDA+to+Provide+Clear+Distinctions+Between+Biosimilars+and+Approved+Biological+Products